FindTrial
Sign In

Magnetic Resonance Imaging of the Brain with and without Contrast

PROCEDURE3 trials

Sponsors

National Cancer Institute (NCI), Ohio State University Comprehensive Cancer Center, City of Hope Medical Center

Conditions

GlioblastomaLocally Advanced Lung Non-Small Cell CarcinomaLocally Recurrent Lung Non-Small Cell CarcinomaMalignant GliomaStage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8

Phase 1

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
CompletedNCT03801902
National Cancer Institute (NCI)Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 +2
Start: 2019-10-28End: 2025-09-04Updated: 2025-09-23
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
RecruitingNCT05136846
Ohio State University Comprehensive Cancer CenterLocally Advanced Lung Non-Small Cell Carcinoma, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8 +6
Start: 2021-12-06End: 2026-12-31Target: 28Updated: 2025-06-04
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
WithdrawnNCT05773664
City of Hope Medical CenterGlioblastoma, Malignant Glioma
Start: 2024-11-15End: 2024-11-29Updated: 2024-09-19

Related Papers

Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer.
Journal of Clinical Oncology2022-06-0116 citations